EMD Millipore (known as Merck Millipore outside the US and Canada), the life science division of Merck KGaA of Germany, has officially opened its US$2m state-of-the-art Biopharmaceutical Technical and Training Centre in Shanghai, China.
The 2,500m2 facility located on the Zhangjiang Hi-Tech Park will provide support, training and validation services to EMD Millipore’s biopharmaceutical customers with operations in China.
The new Shanghai centre
‘We are responding to China’s commitment to strengthen regulatory requirements designed to ensure drug safety,’ said Jean-Paul Mangeolle, head of Merck Millipore’s Process Solutions business.
‘Our new Biopharmaceutical Technical Centre is unique in that we can support and even train our pharmaceutical customers to meet the new Chinese and global regulations.’
The Chinese SFDA and Peking University will use the new centre for training courses specifically created for GMP training and aseptic process manufacturing.
The facility will allow local and regional customers to optimise their upstream and downstream processes with the support of Merck Millipore’s local, regional and international experts.
Merck Millipore operates similar facilities in Singapore, Japan, India, France, North America and Brazil.